Research Progress on the Active Ingredients and Mechanism of Action of Shenling Baizhu San in the Treatment of Ulcerative Colitis

Abstract

Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease that occurs in the mucosa and submucosa of the colorectum and the terminal part of the ileum. Its pathogenesis is related to multiple factors such as environment, genetics, immune dysregulation and intestinal flora disorders. According to the traditional Chinese medicine, this disease belongs to the category of “diarrhea”, “diarrhea” and other diseases, and its main etiology is spleen deficiency and dampness. In the clinical diagnosis and treatment of UC, Western medicine commonly used aminosalicylic acid preparations, glucocorticoids and other drugs, but long-term use of easy to lead to drug resistance and metabolic disorders. In recent years, traditional Chinese medicine (TCM), especially Ginseng and Atractylodes Macrocephalae, has shown unique advantages in relieving clinical symptoms, immunomodulation and improving the quality of life of patients with UC. In this paper, we systematically review the pharmacological effects of the active ingredients (ginsenosides, porinic acid, atractylenolide, etc.) in ginseng saponin and atractylenolide, and elucidate its multi-target mechanism of inhibiting inflammatory response, repairing the intestinal mucosal barrier, and regulating the intestinal bacterial homeostasis through the modulation of the NF-κB, JAK/STAT and other pathways. This paper provides a theoretical basis for the clinical application of ginseng-lingbaijusan and the modernization of compound Chinese medicine, as well as ideas for exploring novel therapeutic protocols for UC and providing more diversified therapeutic options for UC patients.